NCT06966453 2026-03-04
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
Pfizer
Phase 1/2 Recruiting
Clinical Trials
3 trialsNCT06650332 2024-10-21
Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients
Zhejiang Cancer Hospital
Phase 1/2 Recruiting
NCT06378242 2024-07-11
To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
RemeGen Co., Ltd.
Phase 1/2 Recruiting